194 related articles for article (PubMed ID: 1872041)
1. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
[TBL] [Abstract][Full Text] [Related]
2. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
[TBL] [Abstract][Full Text] [Related]
3. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
Kendall MJ; Chellingsworth MC; Jubb R; Thawley AR; Undre NA; Kill DC
Eur J Clin Pharmacol; 1989; 36(3):299-305. PubMed ID: 2744071
[TBL] [Abstract][Full Text] [Related]
5. [Trans-synovial kinetics of tiaprofenic acid].
Kurowski M
Z Rheumatol; 1988; 47(3):173-6. PubMed ID: 3213265
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?
Davies NM
Clin Pharmacokinet; 1997 Dec; 33(6):404-16. PubMed ID: 9435990
[TBL] [Abstract][Full Text] [Related]
7. [Properties and features of nabumetone].
Davies NM; McLachlan AJ
Drugs; 2000; 59 Spec No 1():25-33. PubMed ID: 10841070
[TBL] [Abstract][Full Text] [Related]
8. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
Soma LR; Uboh CE; Rudy JA; Smith MS
Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
[TBL] [Abstract][Full Text] [Related]
9. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
[TBL] [Abstract][Full Text] [Related]
10. [A non-steroidal antirheumatic agent (nabumetone): effectiveness and tolerance in short and long-term use].
Singer F; Kolarz G; Scherak O
Z Rheumatol; 1983; 42(2):82-5. PubMed ID: 6410605
[TBL] [Abstract][Full Text] [Related]
11. Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens.
von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):672-6. PubMed ID: 6526543
[TBL] [Abstract][Full Text] [Related]
12. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
[TBL] [Abstract][Full Text] [Related]
13. Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect.
Světlík S; Štícha M; Matoušková O; Nespěšná L; Sklenář Z; Bartůněk A; Perlík F; Slanař O
Am J Ther; 2016; 23(6):e1498-e1503. PubMed ID: 25393072
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Scott G; Rordorf C; Reynolds C; Kalbag J; Looby M; Milosavljev S; Weaver M; Huff JP; Ruff DA
Clin Pharmacokinet; 2004; 43(7):467-78. PubMed ID: 15139795
[TBL] [Abstract][Full Text] [Related]
15. Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
Dahl SL
Ann Pharmacother; 1993 Apr; 27(4):456-63. PubMed ID: 8477124
[TBL] [Abstract][Full Text] [Related]
16. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection.
Nobilis M; Kopecký J; Kvetina J; Svoboda Z; Pour M; Kunes J; Holcapek M; Kolárová L
J Pharm Biomed Anal; 2003 Aug; 32(4-5):641-56. PubMed ID: 12899954
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and tolerability of nabumetone in the treatment of painful symptomatology of rheumatoid arthritis and osteoarthrosis].
Riccieri V; Spadaro A; Iagnocco A
Clin Ter; 1991 May; 137(3):185-9. PubMed ID: 1831086
[TBL] [Abstract][Full Text] [Related]
18. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
Boelaert JR; Jonnaert HA; Daneels RF; Schurgers ML; Thawley AR; Undre NA; Cooper DL
Am J Med; 1987 Oct; 83(4B):107-9. PubMed ID: 3687998
[TBL] [Abstract][Full Text] [Related]
19. [Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint].
Bolten W; Salzmann G; Goldmann R; Miehlke K
Z Rheumatol; 1989; 48(6):317-22. PubMed ID: 2696292
[TBL] [Abstract][Full Text] [Related]
20. Nabumetone (Relifex)--another NSAID.
Drug Ther Bull; 1988 May; 26(11):41-3. PubMed ID: 3289871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
